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Blockchain systems are a fast emerging and a currently widely discussed novel strategy
for a decentralized cryptographically enhanced digital ledger recording transactions
among stakeholders. This perspective paper looks at its potential uses in the context
of high value and mostly low volume botanical material traded globally and used as
medicines, health foods, in cosmetics and other applications. We offer a perspective
on key areas in the supply of such products globally and how blockchain systems may
help in sustainable sourcing, quality assurance, and in tackling supply problems in cases
of complex multiherbal preparations. Both open and closed blockchain systems are
feasible, and it seems likely that, at least in the initial development, closed ones are
the main ones to be utilized. While blockchain’s potential is not yet clear, the examples
presented here highlight the opportunities of this new technology.
Keywords: blockchain, herbal medicines, traditional medicines, sustainability, value chains, quality
(herbal medicines)
INTRODUCTION
Concerns about the quality and authenticity of botanical material used in medicines and food
have existed at the very least since the start of international trade in such materials. This includes
materials that are used as high value foods, food supplements, cosmetics or herbal medical
products. As highlighted in Figure 1, a broad array of products exist which rely on the supply
of primary material through complex value chains.
The global trade in high value botanical products has increased enormously bringing the challenges
associated with the supply of such products to the center of the debate in ethnopharmacology
and medicinal plant research. Very often the focus has been either on addressing specific quality
problems (e.g., adulteration and poor production systems) or on solving specific concerns in social
or economic terms. These challenges were generally addressed by defining quality standards, for
example, in a pharmacopeia (for medical products) or in industrial QC standards (esp. for food and
cosmetic products). These supply systems also gave rise to a number of specific concerns including
equitable benefit-sharing/responsible sourcing and sustainable supply, especially as it relates to
protected or threatened environments. In many cases this had been seen as a supply issue, but
at least since 2012 an increased awareness has developed on the wider role of such herbal materials’
value chains in a globalized market (Booker et al., 2012).
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FIGURE 1 | The food-medicine interface: where to draw the line?
This links to a series of core characteristics of this sector,
which include:
– The material may be collected from the wild or cultivated
and the supply may be based on a mix of the two
– Presence of a large number of primary producers, who
often produce small quantities of materia prima
– These materials enter complex value chains, often
requiring middlemen to link to international purveyors
– Knowledge about the product characteristics along these
value chains is often limited
– Lack of knowledge about and often poor practice relating
to endangered/overharvested species
– Dramatic increase in price from primary producer to end
users
– The regulatory status and subsequent commercial
expectations differ in various markets. A specific botanical
drug may yield a licensed medicine in one market and an
unregulated food supplement in another one
While Booker et al. (2012) highlighted the opportunities
arising from analyzing value chains using a transdisciplinary
approach, more recent developments may offer a new solution –
blockchain systems, a technology now widely seen as an
opportunity to solve the challenges arising from the fast
changing socio-economic framework of how societies exchange
information and goods (trade). This is exemplified by the
launch of Frontiers in Blockchain in September 2018, which
publishes rigorously peer-reviewed research covering theory and
applications of blockchain and blockchain-related technologies1.
Therefore, in this perspective article we explore the opportunities
in using blockchain systems in a sector that is dominated
by many stakeholders, and specifically, how this can help to
ascertain equitable benefits to producers, sustainable sourcing
and production, and the best quality of the final products.
THE CONCEPT OF BLOCKCHAIN
Key in the exchange of goods and information is knowledge
along a value chain of what is being exchanged including specific
requirements relating to a products’ composition, quality, source,
and many other relevant data, traditionally stored in analog
‘ledgers.’ Blockchain (BC) – as opposed to the “traditional”
centralized system – is a system of decentralized data storage that
is built on a net of users, each of which can become a node of
the network (Figorilli et al., 2018). Any new information (stored
in blocks) is linked to other blocks containing previous data,
forming a chain of information and thus a history of interactions
which is stored and copied in all the nodes within the network.
Validation prior to incorporation into the BC is a key feature.
Therefore, each computer is an official custodian of one copy
of that blockchain. There will be as many identical copies of the
blockchain as there are computers in the network, allowing for a
more efficient identification of corrupted data and their control.
Data on the BC is unmodifiable as, in practice, all that can be
modified is a single copy of the BC, which then, compared to all
1https://www.frontiersin.org/journals/blockchain#
Frontiers in Pharmacology | www.frontiersin.org 2 April 2019 | Volume 10 | Article 396
fphar-10-00396 April 17, 2019 Time: 16:26 # 3
Heinrich et al. Unblocking High-Value Botanical Value Chains
FIGURE 2 | A general overview of the various stages of value chains of botanical products and how these could be managed using blockchain systems. Levels of
complexity range from low ( ) to very high ( ).
the other copies, will be different, and could be easily singled out
and flagged as wrong/corrupted. There seems to be no shortcut
to modify more than one copy at one time (Carson et al., 2018;
Saberi et al., 2019).
On the other hand, it is easy enough to grasp how a
“traditional” centralized system suffers data corruption. A failure
of the main computer, or corruption of data stored on it,
results in a spread of the error/modification to all the receivers
connected to Central. Therefore, data security depends on the
security of the central system. This of course translates into
fear and therefore considerable investment in security systems.
Blockchain subsequently becomes a revolutionary way to shift
the issue of data security from external “security providers” to an
internal network of “trust,” which is free of charge.
In 2018 Galvez et al. (2016) argued convincingly, that there
are enormous opportunities (but also major obstacles) for using
blockchain approaches in the food sector. Their focus is in
essence on the optimisation of industrial processes and on the
potential of blockchain system from the perspective of the large
industry. Early stages of production were not covered in any
detail. Obviously, they also did not cover the additional challenge
of securing that the end products will have a therapeutic benefit.
An herbal medical product will not only have to comply with label
claims, but it also must have a composition and quality assuring
therapeutic benefits.
This perspective article introduces how BC systems in
food/herbal markets will greatly benefit a sector relying on
complex transaction networks, often lacking trust in its value
chains (Figure 2). The “trust” is based on transparent exchange
of unmodifiable data, uploaded and securely stored on the
blockchain, bypassing intermediaries in their role of “trust
guarantors” between untrusting parties. Blockchain technology
provides a safe/trusted platform for interactions between such
parties without the need for individual trust to be built. This can
be reinforced by the use of smart contracts (SCs) which can be
embedded into the BC framework. The use of SCs is a way to
efficiently and securely validate a contract in the digital world
creating a negotiation, agreed by all involved parties, whose terms
are defined and need to be fulfilled to “release” the agreed actions
(Carson et al., 2018). In other words, when all the conditions
required in the contract are met, the payment to the respective
parties will be made automatically, assuring a fair and fraud-free
transaction. The benefits of using this technology are:
• Increase in reliability even if the parties do not trust each
other
• Increase of economic benefits, eliminating third party
involvement for mediation, decreasing costs
• All records saved in the blockchain are available to see and
can serve to promote the good practices of the parts
• On the small producer’s side, this technology can help
them to receive almost immediate benefits from the
commercialization
In the following, we used five areas of major concern as case
studies for how such problems might be overcome.
CASE STUDY 1: QUALITY
CONSIDERATIONS IN HERBAL
VALUE CHAINS
The quality assurance of herbal medicinal products is a more
complex process than assuring the quality of pharmaceutical
products. Natural products are typically highly variable in their
chemical composition and any quality assessment must take into
account the long, diverse and often obscure value chains from
which these products originate. While such quality aspects are
commonly controlled in products holding a full pharmaceutical
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manufacturing license and the quality requirements are well-
established using pharmacopoeial methods, quality assurance
cannot be guaranteed, for poorly or unregulated products. Food
standards also exist.
The quality and safety of a product in a short chain, i.e., the
plant is grown and used as a medicine in close proximity or
even grown and used by the same person, is relatively simple
to effectively control, assess, and manage. However, the same
plant when destined for use as a medicinal product or food
supplement on the national market or as an export product
presents far greater risks and consequently greater challenges
to overcome, requiring the collection of complex sets of data
(Booker et al., 2012). Authenticity, purity, and compliance with
the allowed maximum levels of contaminants (microbiological,
heavy metals, and toxic substances) are generally controlled at
a very late stage and importantly, only a small share of such
botanical products is produced under rigorous pharmaceutical
quality control.
Heavy Metal Contamination
Herbal products are prone to heavy metal contamination
for two main reasons: pollution and natural accumulation.
Pollution caused by heavy industry is a particular problem in
fast developing countries, e.g., China and India. Although this
situation has begun to be addressed in some countries, the
legacy of years of pollution finding its way into agricultural
land via the rivers and waterways will take a long time to
remediate. Very often little is known about pollution levels
in specific areas. Secondly, some plants naturally accumulate
heavy metals, e.g., cadmium in Perillia sp. or in Hypericum
perforatum L., and in some areas heavy metals are found in the
subsoil, e.g., cinnabar in rock formations leading to high levels
of mercury in certain species. Only through careful selection of
cultivation sites or strict controls on wild collection can these
problems be minimized.
There is little need for pesticides in the short chain, but global
supply and consumer expectations often require intensively
farmed crops that need higher levels of pesticides to produce high
yields of the desired product commonly at a low cost. In addition,
many of these chemicals may be prohibited under European
legislation. Only through careful management of the value chain
and detailed training as to which pesticides may be used and at
what quantities can we hope to keep pesticides’ residues within
allowable limits.
Mycotoxin
Aflatoxins (mycotoxins produced by Aspergillus spp.) are highly
toxic and carcinogenic, but are regularly found in botanical
materials esp. in the food industry (Liu and Wu, 2010). Certain
types of products are more at risk than others and analysis
has shown high levels of aflatoxins, for example, in wheat,
barley, maize, and nuts, but little has reached the general
media regarding the problems encountered in herbal medicine
manufacture (Williams et al., 2004; Azziz-Baumgartner et al.,
2005; Liu and Wu, 2010). This is partly due to a lack of robust
regulation in many importing countries but also due to a lack of
awareness within the value chain about these problems and their
lethal potential (Williams et al., 2004).
Transportation, storage, or processing are key areas
where blockchain management may help to minimize risks.
Development of aflatoxins in a short value chain is unlikely,
problems arise when fungal molds are given the right conditions
to evolve, typical of global complex value chains. Procedures
employed at a local level, utilizing small quantities of materials,
may be entirely unsuitable for the global distribution of
large consignments and it is vital that this is recognized
and the correct processes and procedures are developed,
implemented, and controlled.
Unintentional Adulteration: Pyrrolizidine
Alkaloids in Saint John’s Wort (SJW)
Products (H. perforatum L.)
In February 2016, six batches of SJW THR products sold in
the United Kingdom, produced in 2013, were recalled due to
having levels of pyrrolizidine alkaloids (PAs) above-the-European
Medicines Agency’s recommendations. These compounds are
associated with potentially very serious health risks (liver toxicity
and cancer) (Letsyo et al., 2017). PAs are not produced by
H. perforatum, but are found in certain species especially
Boraginaceae and some Asteraceae. Therefore, their presence
in SJW herbal preparations is likely due to the presence of
high PA yielding weeds (such as Senecio, Crotalaria, Echium
spp., and others), which had been growing in the SJW fields
and unintentionally harvested along with the desired herb.
It is currently difficult for authorities to identify sources of
the adulterated material and where the incriminated batches
ended. A blockchain system, recording all the movements of
a good, from seed purchase to packaging facilities, retailers,
and perhaps, final customer purchase, would provide easily
accessible information to restrict the recall warning to a
targeted area (e.g., South West United Kingdom), leading to a
faster and more efficient removal of those products from the
market/households. In addition, authorities and general audience
would have the possibility to flag the incriminated batches on the
blockchain itself.
Intentional Adulteration: The Case of
Food Dyes in SJW Products
Studies on the quality of SJW products on the market
(Frommenwiler et al., 2016; Booker et al., 2018), found that
some samples contained undeclared food dyes, which are
likely to have been introduced with the purpose of mimicking
hypericin absorbance in samples containing a considerably
lower concentration of hypericins than good quality ones
(Booker et al., 2018).
The above examples are by no means a definitive list
of quality concerns in herbal medicines, but they present
the majority of risks that can be attributable to lack of
knowledge and good practice along poorly managed value chains.
BC systems are ideal to monitor the individual steps from
the primary production the initial processing and then the
production of a finished product. BC systems offer traceability
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allowing for a faster identification of the source (s) of a
problem, e.g., identification of where along the chain quality
control measures were lacking. Data on good agricultural
and collection practices (GACP), good manufacturing practice
(GMP) can and need to be included in this. Although
we have the capabilities to detect a wide array of quality
failures using the latest analytical techniques, BC systems
will facilitate the traceability of quality parameters, with the
initial steps requiring far lower level of validation, than the
subsequent ones.
CASE STUDY 2: SUSTAINABLE
SOURCING
At present there are many cases of sustainability problems
(Schippmann et al., 2002), which resulted in withdrawal of some
products from regulated market (e.g., Drosera spp. previously
used in European phytomedicine) or again in adulterations.
In the 1970s African cherry, Prunus africana (Hook.f.)
Kalkman, became popular as a phytomedicine for its positive
effect in benign prostatic hyperplasia (BPH) (Stewart, 2003;
Bodeker et al., 2014). Since then the approval of a patent and
several licenses, exponentially increased the demand leading
to vast illegal harvesting. High rates of poverty in countries
supplying P. africana, a crop playing an important role in the
subsistence of villagers, together with the lack of regulation
of the governments involved in the value chains (both on the
side of the primary producer and the end consumer) drove the
overexploitation of P. africana out of control. This resulted in it
becoming an endangered species (Bodeker et al., 2014).
Warburgia salutaris’ case (W. salutaris (G. Bertol.) Chiov.)
is more dramatic, as this medicinal plant has not only been
classified as Endangered in Swaziland (Dludlu et al., 2017),
but its population is steadily shrinking due to illegal trading
and uncontrollable harvesting. Its increasing popularity as a
traditional medicine contributed to its overexploitation, resulting
in its classification as Extinct in the Wild in Zimbabwe (Botha
et al., 2004; Dludlu et al., 2017).
Based on recent changes in the supply of goods, increasing
awareness and the many concerns associated to- the dramatic
environmental changes, consumers are demanding more
information about the products they are purchasing. According
to the Ethical Consumer Markets Report 2017 the main
growth in consumers’ spending was driven by sustainability
certification of the goods, as Certified Sustainable Seafood
MSC and Rainforest Alliance (Ethical Consumer Research
Association [ECRA], 2017). The use of BC technology can
firstly aid in monitoring collection and processing of these
materials, providing important baseline data on what is actually
harvested/collected. This can improve sustainable production,
as all the detailed information of the product will be available
for the participants of the value chain. If sustainable production
systems are developed, BC systems can certify the sourcing in
these production systems. Geotracking and information on the
initial processing can prevent overexploitation and help defining
better production systems.
CASE STUDY 3: BENEFITS TO
PRODUCERS OF THE MATERIA PRIMA
The benefits to primary producers remain a hotly contested
area. Very often financial benefits are limited. Whereas relatively
well established farming businesses in the developing South may
be able to connect to international trade, small farmers and
farm workers are unlikely to have resources or capabilities to
form business relationships with manufacturers and retailers of
herbal medicinal products in the industrial North. However,
for farmers and primary producers who established more
sophisticated operations and managed to form these relationships
with international partners, there are advantages for producers,
manufacturers, and end-consumers of these products.
As Booker et al. (2012) highlighted for turmeric, in a
traditional value chain, whereby the farmer sells the product at
an auction house, the farmer has relative autonomy over how the
crop is cultivated and could sell it for the highest price available.
However, turmeric price varies considerably from year to year
and if the price is low the farmers often choose to store the
crop rather than sell, resulting in long-term storage under poor
conditions, using chemical treatments (pesticides and fungicides)
to prevent deterioration with serious implications for the quality
of the end product.
In the second model presented, a company established a direct
contract with the farmer, agreeing on a price for a quantity of raw
material early on in the process and, once cultivated, transferred
directly to the product manufacturer. This system demonstrated
some benefits to the farmer as it provided better market stability,
knowledge of the quantities to grow and an agreed price which
could be negotiated beyond the typical market price. In return,
the manufacturer could exert greater control over the chain and
request specific private standards (organic production, national
standards) (Booker et al., 2012). Moreover, any welfare benefits
passed to the farmer in terms of employment stability, price
stability or price premiums could be utilized for companies’
overall marketing and advertising strategy. The potential benefits
to the end consumer were access to higher quality and more
socially responsible products.
Currently there are few checks to ensure that contracts,
processes, and procedures are adhered to by either party.
Whereas some companies are well established in the market,
having built up trusting relationships with partners over a period
of years, there is no barrier to prevent a “me too” type marketing
strategy but one that lacks the necessary skills and infrastructure
to actually produce a product of quality and with little scope for
any meaningful welfare benefits.
Here, BC systems will offer transparency both ways; it will be
apparent to both consumers and producers what the economic
benefits and the resulting values are. It may enable more direct
links between (groups of) producers and the relevant companies
producing the finished product, either for the national market of
origin or the non-domestic destination.
In a very similar way, BC systems can be used to provide
evidence for organic and sustainable sourcing. Consumers would
acquire a final product knowing exactly where it came from
locally sourced, what type of certification it has (reliability) or
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its production’s social and environmental impact. As BC-stored
information is immutable, consumers would purchase products
with more confidence as there will be no information bias based
on the retailers’ own benefit.
CASE STUDY 4: CHINESE MEDICINE
MARKET: AN EXAMPLE OF ADDED
COMPLEXITY WITHIN THE
VALUE CHAIN
Traditional medicinal products as used in traditions like
Indian, Chinese, African or American medical systems pose
many problems that are similar to those of other value
chains of high value botanical products. However, the very
different approaches to the use of these resources, based
on their unique underlying philosophies, result in some
specific challenges, when translated into the globalized and
interconnected markets. Crossovers between value chains based
on traditional practices to ones that result in globally recognized
products are likely. The source material itself (i.e., the
species and botanical drug) is often complex, encompassing
species or drugs that outside of the country of origin
may not be permitted or might be regulated differently,
incurring in numerous problems regarding the supply of
the correct material. In addition, complex processing of the
botanical material in the early steps of the value chain, is
often required as it is seen as improving the ingredient’s
therapeutic usefulness.
Here, we use Traditional Chinese medicine (TCM) to
highlight some key challenges. Over 90% of the TCM herbal
market is constituted by formula products, remedies typically
containing between three and ten ingredients, often produced
in ways which are unique to TCM (Scheid et al., 2009).
Consequently, a range of complex development, manufacturing,
and retail challenges exist. This dramatically increases potential
risks of poor quality, adulteration or other quality problems.
Therefore, it is essential for the future of Chinese herbal
formulas that, for example, each raw material used is traceable
including a documented record of its progressing along the chain.
A blockchain would allow to record and verify that the correct
source material had been used within the formula and that any
primary processing has been carried out according to defined
procedures, ideally well-defined industrial standards (i.e., SOPs –
standard operating procedures).
Traditional Chinese formula products have had difficulty
in finding a stable and secure regulatory position within
markets outside of China. This situation arises chiefly because
these products are manufactured in Asia to Asian standards,
often for Asian markets. When they become global products,
the legal requirements of the importing countries are often
not or only partially considered. Sometimes commercialization
abroad is attempted by straddling the hazy interface between
food and medicine.
The TCM formulation “Eight-Gem decoction” comprises
eight Chinese herbs, in China recognized as both medicines
and food. All the ingredients are commonly used in TCM
and widely cultivated. However, the sources of “Eight-Gem
decoction” materials are variable. In this specific formulation,
some of the materials require extra processing (as described in
Table 1). Steaming and frying are not uncommon requirements
in TCM preparations, as such steps are meant to change or
enhance/limit the activity of that ingredient (Wu et al., 2018).
An example of the problem of conversion for different
markets is Rhodiola spp., a widely used remedy. R. rosea
L. is the species traditionally used for herbal medicine in
Europe while in TCM R. crenulata Hook.f. and Thomson
is the only accepted species. R. rosea products were found
to contain R. crenulata indicating confusion in species
authentication (Booker et al., 2016). Another example is
Glycyrrhizae Radix, one of the most frequently used TCM
materials (Gancao). Based on the Chinese (2015) and British
(2018) Pharmacopeia the current official source species are
Glycyrrhiza uralensis Fisch., G. inflata Bat., and G. glabra L.
but the United States and Japanese pharmacopeia only accept
the first two species (Wu et al., 2015). Other G. species and
varieties are locally called as “Gancao” but they are not listed in
any pharmacopeia.
Using blockchain systems, a complex process which may result
in products used in a more traditional context (i.e., within TCM
in China) or for a globalized market could be clearly documented
providing transparency for suppliers, processors, and end-users.
CASE STUDY 5: INTELLECTUAL
PROPERTY QUESTIONS
Intellectual Property Rights have become much contested in
the area of herbal (medical) products and the abidance to
TABLE 1 | “Eight-Gem decoction” – Botanical drugs and their processing.
Drug name
(International)
Species Common name Optional
processing
Ginseng Radix et
Rhizoma
Panax ginseng
C.A. Mey
Renshen/Ginseng Steaming
Atractylodis
Macrocephalae
Rhizoma
Atractylodes
macrocephala
Koidz
Bai zhu Frying
Poria Poria cocos
(Schw.) Wolf
Fuling
Angelicae Sinensis
Radix
Angelica sinensis
(Oliv.) Diel
Danggui/Chinese
Angelica
Frying with Chinese
yellow wine
Chuanxiong
Rhizoma
Ligusticum
chuanxiong Hort
Chuanxiong –
Paeoniae Radix
Alba
Paeonia lactiflora
Pall
Bai shao Frying
Rehmanniae Radix
Praeparata
Rehmannia
glutinosa Libosch
Shu Di Huang Steaming with
Chinese yellow
wine
Glycyrrhizae Radix
et Rhizoma
Praeparata cum
Melle
Glycyrrhiza
uralensis
Fisch./G. inflata
Bat./G. glabra L.
Zhi Gan Cao/Fried
Chinese liquorice
Frying with honey
and Chinese yellow
wine
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international agreements and national laws is now an essential
element of any rational development of a new herbal product. As
seen throughout history, commercialization of genetic resources
and local knowledge without mutually agreed benefit-sharing has
led to exploitation and often has stained relationships between
countries. Despite the existence of the Convention on Biological
Diversity (CBD), Intellectual Property on biodiversity and
genetic resources is seldom respected, as the convention does not
result necessarily in prosecution. One very recent example is that
of maca, Lepidium meyenii Walp., a Brassicaceae native of Peru.
Its hypocotyl has been exported to China without well-defined
and mutually agreed terms and conditions for its development
and it is now widely cultivated especially in China for commercial
purposes (Heinrich and Hesketh, 2018). China has become the
largest maca producer and is now the prime competitor of Peru
for maca’s sales. This “transaction” was never released under an
agreement on benefit-sharing with the Peruvians (the owners
of the natural resource) and it is therefore to be considered
illegal, but what can be done now? Boycott Chinese products?
That would only be possible if we were to know exactly where
each product came from, as food supplements product do not
have to state the material provenance. A blockchain could
provide the information necessary and make data about each step
transparent for authorities in CBD-abiding countries to block
the sale of illegal products and for consumers to make informed
ethical purchases.
CONCLUSION: BLOCKCHAIN SYSTEMS
AND THE GLOBAL TRADE IN
BOTANICAL HIGH VALUE MATERIALS
Food value chains share many challenges and bottlenecks with
herbal medicine value chains, and the United Kingdom’s Food
Standard Agency (FSA) is already looking into how to implement
the food value chains using blockchain technology (for example,
in slaughter houses) (FSA, 2018). Additionally blockchain
systems in farming and agriculture are being investigated and
it is plain to see how the benefits would also apply to herbal
production. The question to address is then: “What makes the
herbal supply blockchain different from any other cultivated food
(coming from abroad)?” and “how do we address these specific
issues in the blockchain?”
There are diverse types of BC systems that could be used
and, while not exhaustive here we only highlight some general
requirements. A closed blockchain technology, with its easily
accessible upload and storage of information, could be a feasible
answer to address most of the quality issues along the herbal
value chain. For example, the raw material can be traced in its
provenance and its movement followed ascertaining traceability
(e.g., indicating material cultivated in an area with heavy soil
pollution). This material would then be subjected by the local
(end-market) authority to specific and relevant tests (to make
sure it meets the standards of the country where it is being
marketed), or otherwise rejected at an early stage. An open
blockchain system would impact more strongly on the way how
such products are traded reducing the need for intermediaries
and middlemen and making transactions very transparent.
One must, however, ask very carefully whether the new drive
to use Blockchain systems is just another hype which will not
fundamentally change the challenges, or whether it will actually
lead to a more sustainable and equitable supply of high quality
botanicals. It is not yet possible to assess this at this stage, nor is
it possible to decide conclusively on open vs. closed blockchain
systems. This paper is a call for exploring opportunities and
limitations. Importantly, we will only see a change if this is
developed into a sector wide standard. It will not prevent quality
problems in general or adulterations, but it will, hopefully, result
in a much better traceability allowing all stakeholders to identify
and then to resolve problems.
In conclusion, the use of blockchain is now discussed widely,
both in areas which are highly regulated by the state (e.g.,
medicines or specific traditional financial services) and also in
less or self-regulated systems (e.g., bitcoinTrade). The trade in
high value botanical products represents a prime opportunity
to explore the potential and limitations of this technology due
to ease of use (if appropriate tools are developed), its versatility
and low cost. It will not solve all the problems along the
value chains of such products, but offers a mechanism for high
quality producers to ascertain their efforts in securing such
quality can be documented. Importantly, a Blockchain will not
prevent problems directly, but the increased traceability will
make it easier to resolve problems. Also, it must be assessed how
erroneous entries into a BC will impact on the system’s usefulness.
In general, blockchain systems will provide a much easier
way to trace a product from ‘field to fork’ (Figure 2). A
certification of compliance with blockchain requirements would
offer consumers a range of trusted products. Overall, the
numerous challenges along these value chains will become
considerably more transparent and, as such, clear guide to
what represents best practice in the supply of such high
value botanicals. With this perspective paper we hope to open
a discussion within ethnopharmacology and natural product
research on blockchains’ potential, uses and limitations.
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